Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AMW GmbH logo — Controlled drug delivery for superior treatment. For patient...

AMW GmbH

Controlled drug delivery for superior treatment. For patients, worldwide.

Founded 2008 Germany Germany 97 employees Total: $45.00M Health Care, Medical Devices +1

General Information

Company Name AMW GmbH
Founded Year 2008
Location Germany Germany
Founders / Decision Makers
Team member
Employees 97
Industries Health Care, Medical Devices, Pharmaceutical
Business Model B2B, B2B2C, White Label
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with AMW GmbH. To contact AMW GmbH, visit amw-pharmaceuticals.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AMW GmbH compare?

A PDF of AMW GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AMW GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AMW GmbH

AMW GmbH, a specialty pharmaceutical company headquartered in Germany, is making strides in the fields of Health Care, Medical Devices, and Pharmaceutical industries. Established in 2008, this innovative company focuses on developing biodegradable controlled-release drug delivery systems, aimed at enhancing patient adherence and offering cost-effective therapies.

The company leverages its extensive expertise in formulation development, forming global collaborations with partners in the pharmaceutical and biotech sectors. AMW covers the entire value chain, from development through to manufacturing and international commercialization, functioning through direct sales and out-licensing.

Among its achievements, AMW GmbH has developed two approved medicinal products—implants releasing goserelin and leuprorelin. The company received its most recent investment as a late-stage VC funding on 01 March 2026 from UVC Partners, signaling strong investor confidence in its cutting-edge solutions and market potential.

Business keywords: Controlled Drug Delivery, Biodegradable Implants, Transdermal Systems, Oncology, Neurology, Pain Therapy, Formulation Development, Pharmaceutical Manufacturing, Drug Delivery Systems, Life-cycle Solutions, Biotech Partnerships, International Commercialization, Out-licensing, Specialty Pharmaceuticals

Services & Products

Drug Delivery Systems
Pharmaceutical Production
Contract Development
Contract Manufacturing
Pharma and Biotech Partnership Support

Target Customers

Pharmaceutical Companies Biotech Companies Patients Worldwide

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC Undisclosed 1
UVC Partners
UVC Partners
01 Mar 2026
Late VC Undisclosed 1
Raiffeisenlandesbank Oberösterreich
01 Sep 2025
Late VC €25.00M 1
European Investment Bank
01 Jan 2018
Series C €6.00M 2
Bayern Kapital SHS Capital
Bayern Kapital, SHS Capital
01 Jul 2016
Series B €7.00M -
01 Jun 2015
Series B €7.00M 1
Bayern Kapital
Bayern Kapital
01 Aug 2014

AMW GmbH Alternatives & Competitors

View All Alternatives
AMW GmbH vs
Archimedes Pharma
Archimedes Pharma United Kingdom

Specialty pharmaceutical company developing therapeutics for the treatment of chronic and debilitati...

Acquired
30 employees
Biotechnology, Health Care
Compare AMW GmbH vs Archimedes Pharma
AMW GmbH vs
Strategic Science & Technologies
Strategic Science & Technologies

Innovative technology delivering faster, effective treatments for various therapeutic areas.

Venture round
Biotechnology, Health Care
Compare AMW GmbH vs Strategic Science & Technologies
AMW GmbH vs
Talphera, Inc.
Talphera, Inc. United States

Focused on the development and commercialization of innovative therapies for use in medically superv...

Debt Financing
40 employees
Biotechnology, Health Care
Compare AMW GmbH vs Talphera, Inc.
View all alternatives

FAQ About AMW GmbH

Controlled drug delivery for superior treatment. For patients, worldwide.
AMW GmbH was founded in 2008.
AMW GmbH is headquartered in Germany.
AMW GmbH operates in Health Care, Medical Devices and Pharmaceutical. Its work centres on Controlled Drug Delivery, Biodegradable Implants, Transdermal Systems and Oncology. Its customers include Pharmaceutical Companies, Biotech Companies and Patients Worldwide.
AMW GmbH has a B2B, B2B2C and White Label business model. Its revenue comes from Licensing, Product Sales and Service Fee.
AMW GmbH has approximately 97 employees.
AMW GmbH has completed 6 funding rounds, raising a total of $45.00M.
AMW GmbH offers: Drug Delivery Systems, Pharmaceutical Production, Contract Development, Contract Manufacturing, Pharma and Biotech Partnership Support.
Top alternatives and competitors to AMW GmbH include Archimedes Pharma, Strategic Science & Technologies, Talphera, Inc., Aggrega Pharma, LLC, Axxia Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AMW GmbH and Archimedes Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AMW GmbH, https://bouncewatch.com/company/amw-gmbh, updated 14 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout